• Recruiting

NCT03997968: Phase 1/2: A Phase 1/2 Study of CYT-0851, Oral RAD51 Inhibitor, in B-Cell Malignancies

Updated: May 26

NCT03997968: Phase 1/2: A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors


cyt-0851

A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors


This clinical trial is an interventional, active-treatment, open-label, multi-center, Phase 1/2 study. The study objectives are to assess the safety, tolerability and pharmacokinetics (PK) of the oral RAD51 inhibitor CYT-0851 in patients with relapsed/refractory B-cell malignancies and advanced solid tumors and to identify a recommended Phase 2 dose as a monotherapy and in combination with chemotherapy for evaluation in these patients.


Sponsor

Cyteir Therapeutics, Inc

 

ClinicalTrials.gov Identifier: NCT03997968


Official Title: A Multi-Center, Open Label Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in Patients With Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors


First Posted : June 25, 2019


Click here to see details on ClinicalTrials.gov

 

Drug: CYT-0851

Drug: CYT-0851 in combination with gemcitabine

Drug: CYT-0851 in combination with capecitabine

Drug: CYT-0851 in combination with rituximab and bendamustine

 

CYT 0851


RAD51 Inhibitor CYT-0851 (Code C165436)

CYT 0851

CYT-0851

CYT0851

RAD51 Inhibitor CYT-0851

 

Locations

United States, Arizona

United States, California

United States, Colorado

United States, Florida

United States, Massachusetts

United States, Michigan

United States, Minnesota

United States, New York

United States, New Jersey

United States, Oklahoma

United States, Pennsylvania

United States, Tennessee

United States, Texas

United States, Washington

United States, Wisconsin




Posts Archive